GenMark Diagnostics (GNMK) Tops Q3 EPS by 9c, Sees FY14 Revenue Over $29M

GenMark Diagnostics (NASDAQ: GNMK) reported Q3 EPS of ($0.23), $0.09 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $5.8 million.

The Company also increased its full year 2014 guidance. Total year revenue is now expected to exceed $29.0 million and gross margin is expected to be approximately 54%.

(Street sees EPS of FY14 revenue of $27.83 million)

For earnings history and earnings-related data on GenMark Diagnostics (GNMK) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance
• Immucell Corp (ICCC) Reports Q2 EPS of $0.20